Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune. More
Cripto-1 expression increases the expression of TNF-alpha in CD4+ T cells in tissues affected by chronic inflammatory disease. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Rheumatoid arthritis More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Our Australian based clients have developed a second generation antisense inhibitor to human CD49d, a subunit of VLA-4, that has shown in Phase II studies to be effective in reducing brain lesions in patients with the relapsing form of multiple sclerosis. More
The present technology describes recombinant poxvirus vectors encoding at least three or more costimulatory molecules and TAAs. More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 933 pages - $1,495
Nov 2010 - 308 pages - $1,495
Apr 2011 - 75 pages - $3,800
Nov 2010 - 330 pages - $1,495
Nov 2010 - 527 pages - $1,495
Dec 2010 - 37 pages - $500
Jul 2011 - 136 pages - $500
Feb 2011 - 209 pages - $3,500
Nov 2010 - 40 pages - $500
Dec 2010 - 22 pages - $500
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us